Related Experiment Videos
Anticonvulsants for women with pre-eclampsia
L Duley1, A M Gulmezoglu, D J Henderson-Smart
1Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF. lelia.duley@ndm.ox.ac.uk
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Magnesium sulfate may be the best anticonvulsant for pre-eclampsia, reducing eclampsia risk. However, more evidence is needed to confirm the benefits and risks of anticonvulsants in pregnancy.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
Background:
- Pre-eclampsia is a common pregnancy complication.
- Anticonvulsants are administered to prevent eclamptic seizures and improve maternal and infant outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of anticonvulsants in managing pre-eclampsia.
- To assess the impact of anticonvulsant therapy on both mothers and their newborns.
Main Methods:
- Systematic review of randomized controlled trials.
- Searched Cochrane Pregnancy and Childbirth Group trials register and Cochrane Controlled Trials Register.
- Independent data extraction and quality assessment by two reviewers.
Main Results:
- Magnesium sulfate demonstrated a reduced risk of eclampsia compared to placebo (RR 0.33, 95% CI 0.11 to 1.02).
- Magnesium sulfate was more effective than phenytoin in preventing eclampsia (RR 0.05, 95% CI 0.00 to 0.84).
- Increased risk of cesarean section observed with magnesium sulfate versus phenytoin (RR 1.21, 95% CI 1.05 to 1.41).
Conclusions:
- Insufficient evidence exists to definitively establish the benefits and harms of anticonvulsants for pre-eclampsia.
- Magnesium sulfate is suggested as the preferred anticonvulsant option if treatment is initiated.
- Further research is warranted to clarify the role of anticonvulsants in pre-eclampsia management.